Paris-based venture capital firm Sofinnova Partners has closed its latest early-stage healthcare venture capital fund Sofinnova Capital IX, oversubscribed at €333m (US$371.6m). The firm has more than €2bn under management with more than €1bn raised in the last four years across its platform of life sciences funds. Sofinnova Capital IX will invest in the healthcare…